Cipla partners Premier Medical Corporation to launch COVID-19 rapid antigen test kits in India

By: |
December 16, 2020 10:44 AM

"In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd," Cipla said in a regulatory filing.

The test will be marketed under the brand name 'CIPtest'. (Representational image)

Drug major Cipla on Wednesday announced its partnership with the Premier Medical Corporation Pvt Ltd for commercialisation of the rapid antigen test kits for COVID-19 in India.

“In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd,” Cipla said in a regulatory filing.

The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week.

The test will be marketed under the brand name ‘CIPtest’.

Shares of Cipla were trading 0.29 per cent higher at Rs 783.95 apiece on the BSE.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Over 12.7 lakh healthcare workers received COVID-19 vaccine jabs Friday 6 pm
2Health worker dies days after jab; official says no vaccine link
3India undertaking contractual supplies of coronavirus vaccines to several countries: MEA